

NLRP3 protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/N3B8B570DDADEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: N3B8B570DDADEN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "NLRP3 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in NLRP3 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

NLRP3 protein inhibitors Understanding

NLRP3 protein inhibitors: Overview

The NLRP3 inflammasome regulates the release of pro-inflammatory cytokines in response to "danger signals," including the presence of foreign or endogenous molecules that signal infection, tissue damage or metabolic imbalances. Chronic inflammation driven by improper activation of the NLRP3 inflammasome has been implicated in a wide array of diseases, including fibrotic, autoinflammatory and neurodegenerative diseases, as well as certain cancers. Small molecules that selectively inhibit NLRP3 have well-understood potential to address improper activation and treat chronic inflammation at the source, without broadly suppressing the immune system.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence NLRP3 protein inhibitors R&D. The therapies under development are focused on novel approaches for NLRP3 protein inhibitors.

NLRP3 protein inhibitors Emerging Drugs Chapters

This segment of the NLRP3 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NLRP3 protein inhibitors Emerging Drugs

SB206: Novan

SB206, is a topical antiviral gel for the treatment of viral skin infections. SB206 is currently being evaluated in B-SIMPLE4, a pivotal Phase 3 trial, for the treatment of treatment of molluscum contagiosum, a contagious skin infection caused by the molluscipoxvirus.

NT-0167: Nodthera

NT-0167 is being evaluated in a Phase 1 clinical trial in healthy volunteers. Therapeutics that disrupt the NLRP3 inflammasome to inhibit damaging inflammatory processes have the potential to help patients with many chronic diseases. NodThera's approach to selectively target the NLRP3 inflammasome without broadly suppressing the immune system is an enormously promising strategy for developing therapies that can help the patients

Further product details are provided in the report.....

NLRP3 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different NLRP3 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on NLRP3 protein inhibitors

There are approx. 12+ key companies which are developing the NLRP3 protein inhibitors. The companies which have their NLRP3 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novan.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

NLRP3 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NLRP3 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NLRP3 protein inhibitors therapeutic

drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NLRP3 protein inhibitors drugs.

NLRP3 protein inhibitors Report Insights

NLRP3 protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

NLRP3 protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing NLRP3 protein inhibitors drugs?

How many NLRP3 protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of NLRP3 protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NLRP3 protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for NLRP3 protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novan

Novartis

Nodthera

Zydus Cadila

Ventus Therapeutics

Monte Rosa Therapeutics

Roche

Inflazome

Ionis Pharmaceuticals

TWi Biotechnology

Key Products

SB206

DFV 890

NT 0167

ZYIL-1

SB 206

Research programme: NEK7 targetting anti-inflammatories

Research programme: NLRP3 inflammasome inhibitors

IZD-334

Research programme: NLRP3 antisense oligonucleotides

RG 6418

Diacerein

IZD-174

Contents

Introduction

Executive Summary

NLRP3 protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

NLRP3 protein inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

SB206: Novan

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

DFV 890: Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

NT 0167: Nodthera

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Research programme: NLRP3 inflammasome inhibitors - Roche

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

NLRP3 protein inhibitors Key Companies

NLRP3 protein inhibitors Key Products

NLRP3 protein inhibitors- Unmet Needs

NLRP3 protein inhibitors- Market Drivers and Barriers

NLRP3 protein inhibitors- Future Perspectives and Conclusion

NLRP3 protein inhibitors Analyst Views

NLRP3 protein inhibitors Key Companies

Appendix

I would like to order

Product name: NLRP3 protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/N3B8B570DDADEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N3B8B570DDADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970